eClinical Technology and Industy News

CureVac’s COVID-19 mRNA vaccine protects mice against aggressive coronavirus variant

Excerpt from the Press Release:

The preclinical study found CureVac’s candidate, dubbed CVnCoV, protected mice against COVID-19 in a virus challenge study with the B.1.351 variant of the SARS-CoV-2 virus. The variant, first identified in South Africa, bears certain mutations that make it more contagious than the original virus.

It marks the first mouse challenge study that shows complete protection against a highly infectious form of coronavirus variant, CureVac Chief Scientific Officer Igor Splawski, Ph.D., noted in a statement. The results were published on the preprint site bioRxiv.

In collaboration with scientists at Germany’s Friedrich Loeffler Institute, CureVac tested CVnCoV in mice expressing human ACE2 protein. The novel coronavirus uses its spike protein to bind to the ACE2 protein on the surface of human cells to gain entry and spark infection.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?